Fig. 4
From: CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy
The in vivo efficacy of CS1003 was evaluated in an established MC38-hPD-L1 model (a and b) and a parental MC38 syngeneic model (c). All antibodies were administered intraperitoneally (i.p.) every 3 days (Q3D). Mean ± SEM, n = 8.
